On February 20, Evopoint Biosciences announced the successful completion of a 700 million yuan Series E financing round. This round was jointly led by Tencent Investment and Guoxin Investment, with participation from multiple institutions including Jinan Industrial Development, Huakong Investment, Yuankai Capital, Chenhai Capital, Pudong Venture Capital, and Zhuopu Capital. Existing shareholder True Heart Capital continued its support, while Xingyuan Zhicheng served as the exclusive financial advisor for this round.

According to the press release from Evopoint Biosciences, the proceeds from this round of financing will be mainly used to advance the clinical trials of the company’s multiple pipelines, enhance the three major self-innovated technology platforms targeting therapy, anti-infection, and protein degradation chimeras, accelerate the operation of production bases and the construction of commercial teams, and promote the early market entry of products to benefit a wide range of patients.

Public information shows that Evopoint Biosciences was founded in 2017 and is committed to providing high-quality solutions for significant unmet clinical needs worldwide. Based on its self-innovative technology platforms, Evopoint Biosciences has developed a pipeline of innovative drugs, including BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and next-generation antibody-drug conjugates (ADCs), covering disease areas such as cancer, multidrug-resistant bacterial infections, and metabolic disorders.

Currently, the company has nine products in clinical development. Two of these products have entered Phase 3 clinical trials: XNW4107, a next-generation broad-spectrum β-lactamase-resistant antibiotic; and XNW3009, a next-generation uric acid lowering drug. In the field of oncology, Evopoint Biosciences’ next-generation EZH2 inhibitor, XNW5004, has demonstrated promising anti-tumor efficacy in indications such as hematological malignancies and prostate cancer, and is currently in Phase 2 clinical trials. Evopoint Biosciences has partnered with Merck (MSD) to conduct combination therapy clinical trials of XNW5004 with the PD-1 inhibitor Keytruda. Additionally, the company’s next-generation ADC drugs, XNW27 and XNW28, are in Phase 1 clinical trials and have already shown good efficacy and potential for a high therapeutic window.

News on February 19: Beyang Therapeutics recently secured tens of millions of RMB in a Pre-A+ round of financing to accelerate the IND registration and application research for its R&D pipeline in ophthalmology and oncology in China and the United States. This round of financing was exclusively invested by Yuanjin Venture Capital. It is reported that this marks a new progress for Beyang Therapeutics after announcing the completion of its Pre-A round of financing in July 2023. In July last year, Beyang Therapeutics announced the completion of a Pre-A round of financing worth tens of millions of RMB, led by Juming Venture Capital, with Tianxiang Industry and Saintway Pharmatech as follow-up investors.

Beyang Therapeutics was founded in April 2021 and is headquartered in the Biomedical Industry Park of Suzhou Industrial Park. Hu Qiyue, the founder and CEO of the company, has over 20 years of experience in global new drug development and extensive early-stage development expertise across multiple therapeutic areas for both small molecule and biologic drugs. In addition, Beyang Therapeutics has established the ExCEED technology platform, which integrates computational modeling with wet-lab techniques to enhance early drug discovery capabilities through three core aspects: molecular design, drug-likeness optimization, and biological evaluation, enabling the sustainable incubation of projects with best-in-class potential.

Ophthalmology and oncology are key areas of focus for Beyang Therapeutics. Public information shows that Beyang Therapeutics has independently developed multiple project pipelines, among which the first two projects, BT01001 and BT01002, are advancing with IND registration application studies in China and the United States. BT01001 is a small-molecule eye drop designed to target fundus diseases; this product has demonstrated significant advantages in preclinical efficacy and safety data and is currently undergoing clinical registration application studies. BT01002 is a small-molecule inhibitor, with the first proposed indication being a subtype of high-risk leukemia that is difficult to treat upon recurrence.

On February 18, Hangzhou Guiling Medical Device Co., Ltd. ("Guiling Medical" for short) announced the completion of a multi-million-yuan A+ round of financing, which was exclusively invested by Lanwan Sci-Tech Group. The funds raised from this round of financing will be used for the research and development registration, expanded production, and commercialization of Guiling Medical's product pipeline, accelerating its leading position in the wound management sector.

GuiLing Medical, founded in 2017, is dedicated to providing a full set of innovative solutions for infection and difficult-to-heal wounds, ranging from precise debridement to prognosis management. The company has established three major product pipelines: precision surgery, advanced care, and healthy living, encompassing more than ten products including Machete, Bone Regeneration, Full Degradable Bone, QuanVision, and QuanEncounter, to meet the comprehensive wound management needs of different patients across all stages.

Among them, Machete is a precision debridement waterjet power system used for wound bed preparation / axillary odor treatment; SECCS system is a bone marrow blood puncture aspiration circulation device suitable for clinical patients with bone defects and nonunion; Fully Degradable Bone is a high-purity fully degradable local drug sustained-release carrier, suitable for solving the pain point of postoperative infection in clinical practice.

According to a press release by Guiling Medical, the SECCS Bone Regeneration System is a Class III medical device led by Academician Kerong Dai from the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine. It can rapidly extract and enrich mesenchymal stem cells from bone marrow blood in just 7 minutes during surgery, preparing bioactive bone that significantly enhances bone regeneration capability. This allows bone repair speed to be consistent with autologous bone without the risk of allogeneic immune rejection. The product can be used in all surgical procedures requiring bone grafting in clinical practice. Its unique innovative features help more patients achieve clinical benefits and are expected to become the future direction of bone repair technology. This technology also integrates Guiling Medical’s precision surgical product line, including the precise debridement technology of the Machete series and the localized infection control technology of the fully degradable bone graft material, providing an innovative comprehensive solution for orthopedic doctors and patients in China.